ATE298790T1 - Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung - Google Patents

Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung

Info

Publication number
ATE298790T1
ATE298790T1 AT94927860T AT94927860T ATE298790T1 AT E298790 T1 ATE298790 T1 AT E298790T1 AT 94927860 T AT94927860 T AT 94927860T AT 94927860 T AT94927860 T AT 94927860T AT E298790 T1 ATE298790 T1 AT E298790T1
Authority
AT
Austria
Prior art keywords
pharmaceutical compositions
pharmaceutical composition
composition containing
endotoxin
relates
Prior art date
Application number
AT94927860T
Other languages
English (en)
Inventor
Klaas Poelstra
Machiel Josephus Hardonk
Winston Willem Bakker
Dirk Klaas Fokke Meijer
Original Assignee
Pharmaaware Ip B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaaware Ip B V filed Critical Pharmaaware Ip B V
Application granted granted Critical
Publication of ATE298790T1 publication Critical patent/ATE298790T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
    • C12Y301/03001—Alkaline phosphatase (3.1.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
AT94927860T 1993-08-13 1994-08-10 Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung ATE298790T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/NL1993/000171 WO1995005455A1 (en) 1993-08-13 1993-08-13 Pharmaceutical composition comprising phosphatase or a derivative thereof
PCT/NL1994/000189 WO1995005456A1 (en) 1993-08-13 1994-08-10 Pharmaceutical composition comprising phosphatase or a derivative thereof

Publications (1)

Publication Number Publication Date
ATE298790T1 true ATE298790T1 (de) 2005-07-15

Family

ID=19861990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927860T ATE298790T1 (de) 1993-08-13 1994-08-10 Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung

Country Status (10)

Country Link
US (1) US6290952B1 (de)
EP (1) EP0721501B1 (de)
JP (1) JP3835811B2 (de)
AT (1) ATE298790T1 (de)
AU (3) AU4835693A (de)
DE (1) DE69434414T2 (de)
DK (1) DK0721501T3 (de)
ES (1) ES2244956T3 (de)
PT (1) PT721501E (de)
WO (2) WO1995005455A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2177666T3 (es) 1995-05-25 2002-12-16 Ngk Insulators Ltd Remedio para la endotoxinemia y disfunciones de organos multiples inducidos por la misma.
JP2002533679A (ja) * 1998-12-21 2002-10-08 フアーマアウエア・アイピー・ベー・ブイ アルカリホスファターゼのｌｐｓ−結合部分を使用する敗血症の診断
US7011965B2 (en) * 2001-03-09 2006-03-14 Regents Of The University Of Minnesota Compositions and methods for stimulating wound healing and fibroblast proliferation
US7888372B2 (en) * 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030232401A1 (en) * 2002-06-12 2003-12-18 Pugia Michael J. Bacterial test method by glycated label binding
US20040052851A1 (en) * 2002-09-16 2004-03-18 Graff Allan H. Modified release oral dosage form
AU2003298036A1 (en) * 2002-12-12 2004-07-09 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7048914B2 (en) * 2002-12-12 2006-05-23 Zoltan Laboratories Placental alkaline phosphatase to control diabetes
US7374754B2 (en) * 2003-09-02 2008-05-20 Essential Skincare, Llc Use of placental alkaline phosphatase to promote skin cell proliferation
US20110142817A1 (en) * 2004-02-04 2011-06-16 Pharmaaware Sepsis B.V. Means and method for treating and/or preventing necrotizing enterocolitis
AU2005210581B2 (en) * 2004-02-04 2010-06-24 Am-Pharma B.V. Use of alkaline phosphatase for the detoxification of LPS present at mucosal barriers
PL1759001T3 (pl) * 2004-04-21 2011-09-30 Alexion Pharma Inc Koniugaty dostarczane do kości i sposób ich zastosowania do nakierowywania białek do kości
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
GT200600512A (es) * 2005-12-15 2007-06-28 Enzimas para reducir el estres inmunologico
EP1965830B1 (de) * 2005-12-28 2014-05-14 Zoltan Laboratories Llc Verwendung von alkalischer phosphatase zur erhaltung von gesunder gewebemasse bei säugetieren
EP1985697A1 (de) * 2007-04-27 2008-10-29 AM-Pharma B.V. Modifizierte Phosphatasen
US8784805B2 (en) 2008-02-29 2014-07-22 Alloksys Life Sciences B.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
CA2732438A1 (en) * 2008-08-29 2010-03-04 The General Hospital Corporation Methods of modulating gastrointestinal tract flora levels with alkaline phosphatase
WO2011100543A2 (en) * 2010-02-12 2011-08-18 The General Hospital Corporation Methods of reducing or inhibiting toxic effects associated with a bacterial infection using alkaline phosphatase
CN103153344A (zh) 2010-04-30 2013-06-12 阿莱克森国际制药有限公司 用于治疗基质矿化障碍的方法、组合物、和试剂盒
JP6055779B2 (ja) 2010-12-27 2016-12-27 アレクシオン ファーマシューティカルズ， インコーポレイテッド ナトリウム利尿ペプチドを含む組成物およびその使用方法
EP2620162A1 (de) 2012-01-27 2013-07-31 Life Science Inkubator Enzym-Polymer-Konjugat zur Endotoxin-Detoxifikation
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
DK3461891T3 (da) 2014-01-24 2020-08-10 Am-Pharma Bv Nedstrømsbehandling af en alkalisk phosphatase
WO2015112017A1 (en) 2014-01-24 2015-07-30 Am-Pharma B.V. Chimeric alkaline phosphatase-like proteins
WO2016007873A1 (en) 2014-07-11 2016-01-14 The Regents Of The University Of Michigan Compositions and methods for treating craniosynostosis
JP6787894B2 (ja) 2014-12-05 2020-11-18 アレクシオン ファーマシューティカルズ， インコーポレイテッド 組換えアルカリホスファターゼを用いた発作の処置
CA2973883A1 (en) 2015-01-28 2016-08-04 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
EP3355904A4 (de) 2015-09-28 2019-06-12 Alexion Pharmaceuticals, Inc. Identifizierung wirksamer dosierungsschemata für gewebeunspezifische alkalische phosphatase-enzymersatztherapie von hypophosphatasie
EP3368062A4 (de) 2015-10-30 2019-07-03 Alexion Pharmaceuticals, Inc. Verfahren zur behandlung von craniosynostose bei einem patienten
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
KR20180125979A (ko) 2016-04-01 2018-11-26 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
US10898549B2 (en) 2016-04-01 2021-01-26 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
WO2018175413A1 (en) 2017-03-21 2018-09-27 Synthetic Biologics, Inc. Alkaline phosphatase formulations
KR20190129058A (ko) 2017-03-31 2019-11-19 알렉시온 파마슈티칼스, 인코포레이티드 성인 및 청소년에서 저포스파타제증 (hpp)을 치료하는 방법
AU2019207600B2 (en) 2018-01-09 2025-01-09 Theriva Biologics, Inc. Alkaline phosphatase agents for treatment of neurodevelopmental disorders
EP4275761A3 (de) 2018-03-20 2024-02-28 Theriva Biologics, Inc. Alkalische phosphatasemittel zur behandlung von bestrahlungsstörungen
EP3768302B1 (de) 2018-03-20 2025-05-07 Theriva Biologics, Inc. Intestinale alkalische phosphataseformulierungen
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
KR102795670B1 (ko) * 2019-03-06 2025-04-15 감브로 룬디아 아베 알칼리성 포스파타제를 포함하는 혈액 처리 장치
WO2020227263A1 (en) 2019-05-06 2020-11-12 Synthetic Biologics, Inc. Alkaline phosphate-based oncology treatments
GB2599573A (en) 2019-05-31 2022-04-06 Rhogen Biotech Llc Compositions and methods for detoxifying bacterial endotoxins
EP3975999A4 (de) 2019-06-03 2023-07-19 Theriva Biologics, Inc. Alkalische phosphataseformulierungen und ihre verwendungen
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
US11103628B1 (en) * 2020-04-29 2021-08-31 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US10881781B1 (en) 2020-04-29 2021-01-05 Orth Consulting, Llc Blood processing apparatus and method for detoxifying bacterial lipopolysaccharide
US12611447B2 (en) 2020-09-04 2026-04-28 Alexion Pharmaceuticals, Inc. Methods for treating bone mineralization disorders
AU2022218782B2 (en) 2021-02-12 2026-06-25 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166766A (en) * 1976-08-09 1979-09-04 Wisconsin Alumni Research Foundation Method for quantitative assay of alkaline phosphatase isoenzymes in serum
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
IL58421A (en) * 1979-10-09 1984-01-31 Yeda Res & Dev Production of(2'-5')oligoisoadenylate and pharmaceutical compositions containing it
US4394370A (en) * 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4409332A (en) * 1982-01-12 1983-10-11 Jefferies Steven R Collagen-enzyme conjugates that exhibit no inflammatory response and method for making the same
US4480041A (en) * 1982-07-09 1984-10-30 Collaborative Research, Inc. Use of phosphotriester intermediates for preparation of functionalized liposomes
US4720458A (en) * 1983-10-19 1988-01-19 Sullivan Cornelius W Heat sensitive bacterial alkaline phosphatase
US4782016A (en) * 1985-01-18 1988-11-01 Eastman Kodak Company Analytical element and method for determination of theophylline by enzyme inhibition
US4861597A (en) * 1986-05-20 1989-08-29 Wako Pure Chemical Industries, Ltd. Novel functionallized liposomes and a process for production thereof
US4975278A (en) * 1988-02-26 1990-12-04 Bristol-Myers Company Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US4873035A (en) * 1987-11-25 1989-10-10 Abbott Laboratories Preparation of sized populations of liposomes
US5017501A (en) * 1987-11-25 1991-05-21 Abbott Laboratories Preparation of uniformly sized liposomes encapsulating an aqueous liquid
GB8822738D0 (en) * 1988-09-28 1988-11-02 Medisense Inc Theophylline assay
DE69127482T2 (de) * 1990-02-07 1998-03-19 Abbott Lab Alkalische Phosphatase mit verbesserter spezifischer Aktivität zur Verwendung in Indikatorreagenzien
EP0525188B1 (de) * 1990-04-18 1995-03-01 Takeda Chemical Industries, Ltd. Liposomenzusammensetzung
NL9100434A (nl) * 1991-03-11 1992-10-01 Rijksuniversiteit Farmaceutische preparaten voor de bestrijding van virale infecties en immuundeficientieziekten, de bereiding en toepassing daarvan.
JPH06508780A (ja) * 1991-07-11 1994-10-06 ビーティージー・インターナショナル・リミテッド 移植片材料
US5248590A (en) * 1991-07-22 1993-09-28 Becton, Dickinson And Company Surface modified liposomes
US5413924A (en) * 1992-02-13 1995-05-09 Kosak; Kenneth M. Preparation of wax beads containing a reagent for release by heating

Also Published As

Publication number Publication date
DE69434414T2 (de) 2006-05-18
DE69434414D1 (de) 2005-08-04
EP0721501B1 (de) 2005-06-29
PT721501E (pt) 2005-11-30
AU4835693A (en) 1995-03-14
WO1995005455A1 (en) 1995-02-23
ES2244956T3 (es) 2005-12-16
EP0721501A1 (de) 1996-07-17
DK0721501T3 (da) 2005-08-29
JP3835811B2 (ja) 2006-10-18
US6290952B1 (en) 2001-09-18
AU698331B2 (en) 1998-10-29
JPH09502342A (ja) 1997-03-11
AU1424399A (en) 1999-04-01
WO1995005456A1 (en) 1995-02-23
AU7710194A (en) 1995-03-14

Similar Documents

Publication Publication Date Title
DE69434414D1 (de) Phosphatase oder ein entsprechendes derivat enthaltene pharmazeutische zusammensetzung
AU560251B2 (en) Pharmaceutical compositions of mopidamol
DE69434431D1 (de) Methoden zur behandlung von muskelerkrankungen und muskelstörungen
UA42747C2 (uk) Похідні пептиду,фармацевтична композиція та спосіб стимулювання секреції гормону росту
IL78342A (en) Pharmaceutical composition for treatment of osteoporosis in humans comprising a parathyroid hormone or a fragment thereof
JO2373B1 (en) W-carboxy-aryl diphenyl urease substitutes used as RAV inhibitors
ATE428430T1 (de) Therapeutische zusammensetzungen zur verwendung bei der prophylaxe oder behandlung von durchfall
MY111188A (en) Improvements in or relating to benzothiophenes.
UA48939C2 (uk) Дизаміщені фуранони, способи їх одержання, фармацевтична композиція на їх основі, спосіб лікування запального захворювання, проміжні сполуки
ATE121938T1 (de) Hemmung von muskelschwund und proteinabbau von muskeln bei säugetieren durch tetrazyklines.
JPS6485984A (en) Methylenephosphonoalkylphosphinates, medicinal composition and therapy for abnormal calcium and phosphate metabolism
DE3851776D1 (de) Verwendung von IGF-II zur Behandlung von Knochenkrankheiten.
PT100850A (pt) Composicoes farmaceuticas contendo uma mistura sinergica de um agente uricosurico, em especial,de probenecid, com um agente antagonista de aminoacidos excitantes, em especial,um derivado de quinoxalina substituido e sua utilizacao no tratamento de doencas neurodegenerativas
ES2088006T3 (es) Composiciones farmaceuticas osteoinductivas.
ATE127020T1 (de) Pharmazeutische zusammensetzungen mit eierschalenbestandteilen und ihre herstellung und verwendung.
ATE131060T1 (de) Chenodeoxycholsäure oder ursodeoxycholsäure zur behandlung von erkrankungen der atmungsorgane.
DE59508366D1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
IL133172A0 (en) Diphosphonic acid salts for the treatment of osteoporosis
DE68919673D1 (de) Verfahren zur behandlung und vorbeugung des verlustes von knochenmasse.
DK0585371T3 (da) Aromatiske oligomere forbindelser, som er anvendelige til at imitere bioaktive makromolekyler
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
DK0655251T3 (da) Farmaceutisk præparat til forebyggelse eller behandling af knoglebrud
NO305958B1 (no) Fosfonosulfonatforbindelse, farmasoeytisk preparat inneholdende denne og anvendelse
DE69735091D1 (de) Synergistische, gold und ein corticosteroid enthaltende zusammensetzungen.
TW224943B (en) The pharmaceutical composition for the stimulation of bone formation

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0721501

Country of ref document: EP